Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Lupin announced the launch of Abacavir sulfate, Lamivudine, and Zidovudine Tablets, the generic version of ViiV Healthcare‘s Trizivir. Trizivir is a combination of three nucleoside analogues (reverse transcriptase inhibitors) indicated for the treatment of HIV-1 infection.
RELATED: Infectious Disease Resource Center
Abacavir is converted by cellular enzymes to CBV-TP, which inhibits the activity of HIV-1 reverse transcriptase by competing with dGTP and by incorporating into viral DNA. Lamivudine is phosphorylated to 3TC-TP, which inhibits reverse transcriptase via DNA chain termination after incorporation of the nucleotide analogue. Zidovudine is phosphorylated to ZDV-TP, which inhibits reverse transcriptase by DNA chain termination after incorporation of the nucleotide analogue.
Lupin’s Abacavir sulfate, Lamivudine, and Zidovudine Tablets are available in a 300mg/150mg/300mg strength.
For more information call (866) 587-4617 or visit Lupinpharmaceuticals.com.
